TY - JOUR
T1 - Clinical trial design for local therapies for brain metastases
T2 - a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group
AU - for the
AU - Response Assessment in Neuro-Oncology (RANO) group
AU - Alexander, Brian M.
AU - Brown, Paul D.
AU - Ahluwalia, Manmeet S.
AU - Aoyama, Hidefumi
AU - Baumert, Brigitta G.
AU - Chang, Susan M.
AU - Gaspar, Laurie E.
AU - Kalkanis, Steven N.
AU - Macdonald, David R.
AU - Mehta, Minesh P.
AU - Soffietti, Riccardo
AU - Suh, John H.
AU - van den Bent, Martin J.
AU - Vogelbaum, Michael A.
AU - Wefel, Jeffrey S.
AU - Lee, Eudocia Q.
AU - Wen, Patrick Y.
N1 - Publisher Copyright:
© 2018 Elsevier Ltd
PY - 2018/1
Y1 - 2018/1
N2 - The goals of therapeutic and biomarker development form the foundation of clinical trial design, and change considerably from early-phase to late-phase trials. From these goals, decisions on specific clinical trial design elements, such as endpoint selection and statistical approaches, are formed. Whereas early-phase trials might focus on finding a therapeutic signal to make decisions on further development, late-phase trials focus on the confirmation of therapeutic impact by considering clinically meaningful endpoints. In this guideline from the Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) working group, we highlight issues related to, and provide recommendations for, the design of clinical trials on local therapies for CNS metastases from solid tumours. We discuss endpoint selection criteria, the analysis appropriate for early-phase and late-phase trials, the association between tumour-specific and clinically meaningful endpoints, and possible issues related to the estimation of local control in the context of competing risks. In light of these discussions, we make specific recommendations on the clinical trial design of local therapies for brain metastases.
AB - The goals of therapeutic and biomarker development form the foundation of clinical trial design, and change considerably from early-phase to late-phase trials. From these goals, decisions on specific clinical trial design elements, such as endpoint selection and statistical approaches, are formed. Whereas early-phase trials might focus on finding a therapeutic signal to make decisions on further development, late-phase trials focus on the confirmation of therapeutic impact by considering clinically meaningful endpoints. In this guideline from the Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) working group, we highlight issues related to, and provide recommendations for, the design of clinical trials on local therapies for CNS metastases from solid tumours. We discuss endpoint selection criteria, the analysis appropriate for early-phase and late-phase trials, the association between tumour-specific and clinically meaningful endpoints, and possible issues related to the estimation of local control in the context of competing risks. In light of these discussions, we make specific recommendations on the clinical trial design of local therapies for brain metastases.
UR - http://www.scopus.com/inward/record.url?scp=85039766618&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85039766618&partnerID=8YFLogxK
U2 - 10.1016/S1470-2045(17)30692-7
DO - 10.1016/S1470-2045(17)30692-7
M3 - Review article
C2 - 29304360
AN - SCOPUS:85039766618
SN - 1470-2045
VL - 19
SP - e33-e42
JO - The lancet oncology
JF - The lancet oncology
IS - 1
ER -